Pharmaceuticals

Autoimmune Gastrointestinal Dysmotility Market Growth Projection: Expected to Surpass $2.63 Billion by 2030 at 8.2% CAGR

February 12, 2026February 12, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the autoimmune gastrointestinal dysmotility market from 2026–2035 with trusted insights from The Business Research Company

What is the expected shift in the Autoimmune Gastrointestinal Dysmotility Market’s size between 2026 and 2030?

The autoimmune gastrointestinal dysmotility market has experienced robust expansion over the last few years. This market is projected to expand from $1.82 billion in 2025 to $1.92 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 5.5%. Historically, this growth has been driven by factors such as the rise in autoimmune disease diagnoses, increased gastroparesis prevalence, the expansion of hospital gastroenterology departments, the use of immunosuppressive drugs, and heightened awareness of rare diseases.

The autoimmune gastrointestinal dysmotility market is projected to experience substantial expansion over the coming years. This market is forecast to reach $2.63 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.2%. Several factors are expected to drive this growth during the forecast period, including advancements in early diagnosis, the development of personalized treatment methods, the increasing need for long-term care, the rise of home-based nutrition therapy, and the broadening scope of autoimmune research. Key trends anticipated within this period involve enhanced recognition of rare gastrointestinal conditions, an uptick in the application of immunosuppressive treatments, the widening scope of nutritional and dietary management strategies, a growing embrace of multidisciplinary care models, and an emphasis on sustained symptom management.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24160&type=smp

Which Drivers Are Shaping Strategic Decisions In The Autoimmune Gastrointestinal Dysmotility Market?

The growing number of clinical trials is anticipated to boost the autoimmune gastrointestinal dysmotility market moving forward. These research studies assess the safety, effectiveness, and optimal application of medical interventions, including drugs, biologics, devices, and treatment methods in human participants, aiming to advance medical knowledge and enhance patient care. The surge in clinical trials is largely attributed to expanded regulatory frameworks mandating trial registration, increased investment in pharmaceutical research and development, and the rapid pace of innovation in new therapeutic approaches like immunotherapies and biologics for autoimmune conditions affecting gastrointestinal motility. Clinical trials focused on autoimmune gastrointestinal dysmotility are crucial for developing treatment options by systematically evaluating new immunosuppressive agents, prokinetic drugs, and biologics, pinpointing the best protocols for managing these disorders, and establishing evidence-based methods that lead to regulatory approvals and clinical adoption of innovative therapies for autoimmune-mediated gastrointestinal dysfunction. For example, as reported by ClinicalTrials.gov, a US-based clinical trials registry managed by the National Institutes of Health, the total number of registered clinical studies reached 477,203 by the end of 2023 (comprising 437,493 cumulative and 39,710 new registrations) and further increased to 520,877 by the end of 2024 (comprising 477,203 cumulative and 43,674 new registrations), showing a 9.1% year-on-year rise in total registered studies. Consequently, the increasing volume of clinical trials is stimulating the growth of the autoimmune gastrointestinal dysmotility market. The increasing emphasis on personalized medicine is projected to propel the autoimmune gastrointestinal dysmotility market in the coming years. Personalized medicine involves a medical strategy that customizes treatment and prevention plans based on an individual’s distinct genetic makeup, lifestyle, and environment. The rise of this approach is primarily driven by advancements in genomics, which enable precise identification of genetic variations and the creation of tailored treatments for individuals. Personalized medicine assists in treating autoimmune gastrointestinal dysmotility by adapting therapies to an individual’s genetic profile and specific disease characteristics. This method enhances treatment effectiveness and minimizes adverse effects, providing more targeted solutions for managing complex gastrointestinal disorders. For instance, in February 2024, the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a significant increase from the 12 approved in 2022, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization. Therefore, the growing focus on personalized medicine is a key driver for the growth of the autoimmune gastrointestinal dysmotility market.

What Segment Categories Are Covered In The Autoimmune Gastrointestinal Dysmotility Market?

The autoimmune gastrointestinal dysmotility market covered in this report is segmented –

1) By Treatment Type: Medications, Surgical Interventions, Dietary Management, Physical Therapy

2) By Drug Class: Prokinetic Agents, Anti-Inflammatory Drugs, Immunosuppressive Drugs, Antibiotics

3) By Disease Type: Gastroparesis, Chronic Intestinal Pseudo-Obstruction (Cipo), Functional Dyspepsia, Irritable Bowel Syndrome (Ibs)

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels

5) By End User: Hospitals, Clinics, Home Care Settings, Research Institutions

Subsegments:

1) By Medications: Immunosuppressants, Corticosteroids, Prokinetic Agents, Antiemetics, Antispasmodics, Antibiotics

2) By Surgical Interventions: Gastrostomy, Jejunostomy, Colostomy, Ileostomy, Pyloroplasty, Colectomy

3) By Dietary Management: Enteral Nutrition, Parenteral Nutrition, Gluten-Free Diet, Elemental Diet, Small Frequent Meals

4) By Physical Therapy: Pelvic Floor Therapy, Abdominal Massage Therapy, Neuromuscular Electrical Stimulation (NMES), Biofeedback Therapy, Respiratory Muscle Training, Postural Training

Which Major Industry Participants Are Leading The Autoimmune Gastrointestinal Dysmotility Market Growth?

Major companies operating in the autoimmune gastrointestinal dysmotility market are AbbVie Inc., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Zeria Pharmaceutical Co. Ltd., Ironwood Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., Dr. Falk Pharma GmbH, Rose Pharma LLC, Parvus Therapeutics Inc., CinDome Pharma Inc., Neurogastrx Inc., Renexxion LLC, ISOThrive Inc., Ambrose Healthcare Inc., AnTolRx Inc., Enteralia Bioscience S.r.l., Immunic Inc., Mozart Therapeutics Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/autoimmune-gastrointestinal-dysmotility-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Autoimmune Gastrointestinal Dysmotility Market?

North America was the largest region in the autoimmune gastrointestinal dysmotility market in 2025. The regions covered in the autoimmune gastrointestinal dysmotility market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Autoimmune Gastrointestinal Dysmotility Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24160&type=smp

Browse Through More Reports Similar to the Global Autoimmune Gastrointestinal Dysmotility Market 2026, By The Business Research Company

Autoimmune Disease Diagnosis Market Report 2026

https://www.thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-global-market-report

Autoimmune Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report

Veterinary Autoimmune Disease Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-autoimmune-disease-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795